Skip to main content

Table 3 Hazard ratios for overall survival and severe kidney toxicities ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Covariate   Hazard ratio (95% CI)* P Value
Overall survival    
Gender (male vs. females) 0.97 (0.74-1.28) 0.84
Age (per year) 1.004 (0.99-1.02) 0.49
Duration of Disease (per year) 0.98 (0.94-1.02) 0.30
Previous Surgery (vs. no surgery) 0.62 (0.45-0.84) 0.002
Previous Systemic Therapies (vs. no systemic therapies) 1.48 (1.08-2.01) 0.014
Previous Radiation (vs. no radiation) 0.93 (0.64-1.36) 0.71
Single Metastasis (vs. multiple metastases) 0.66 (0.26-1.35) 0.26
Liver Metastases (vs. no liver metastases) 1.45 (0.86-2.44) 0.17
Bone Metastases (vs. no bone metastases) 1.57 (1.10-2.23) 0.013
Tumor Uptake Score 2 (vs. Uptake Score 1) 0.70 (0.31-1.61) 0.40
Tumor Uptake Score 3 (vs. Uptake Score 1) 0.40 (0.18-0.91) 0.028
Low Dose [90Y-DOTA]-TOC (vs. High Dose) 0.40 (0.17-0.93) 0.03
Intermediate Dose [90Y-DOTA]-TOC (vs. High Dose) 0.64 (0.38-1.06) 0.08
Severe Kidney Toxicity    
Gender (male vs. females) 0.62 (0.33-1.18) 0.14
Age (per 10 years) 0.99 (0.96-1.02) 0.64
Baseline Glomerular Filtration Rate (per 10 mL/min/1.73 m 2 ) 1.23 (1.09-1.39) 0.001
Low Dose [90Y-DOTA]-TOC (vs. High Dose) 0.54 (0.20-1.43) 0.21
Intermediate Dose [90Y-DOTA]-TOC (vs. High Dose) 0.32 (0.11-0.88) 0.027
  1. *Estimates for each co-variable have been adjusted for histology as a categorical co-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other co-variables listed.